Gilead Sciences (GILD) 30-day option implied volatility flat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Gilead Sciences (GILD) Enters Clinical Collaboration with Merck (MRK) to Evaluate Trodelvy in Combination With KEYTRUDA
January 10, 2022 8:31 AM ESTGilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into two clinical trial collaboration and supply agreements with Merck (NYSE: MRK) to evaluate the combination of Gileads Trop-2 targeting antibody-drug conjugate (ADC) Trodelvy® (sacituzumab govitecan-hziy) and Mercks anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in first-line metastatic non-small cell lung cancer (NSCLC). As part of the collaboration, Merck will sponsor a global Phase 3 clinical trial of Trodelvy in combination with KEYTRUDA as a first-line treatment for patients with metastatic NSCLC. Additionally, the companies recently established an agreement whereby Gilead will sponsor a Phase 2... More
